Tvardi Therapeutics Announces Phase 1 Results For TTI-109, Next-Gen STAT3 Inhibitor; Co. Plans To Advance TTI-109 Into STAT3-Driven Dermatologic And Gastrointestinal Diseases, Subject To Additional Funding

Loading news article.

Tvardi Therapeutics Announces Phase 1 Results For TTI-109, Next-Gen STAT3 Inhibitor; Co. Plans To Advance TTI-109 Into STAT3-Driven Dermatologic And Gastrointestinal Diseases, Subject To Additional Funding | WAPE

Tvardi Therapeutics Announces Phase 1 Results For TTI-109, Next-Gen STAT3 Inhibitor; Co. Plans To Advance TTI-109 Into STAT3-Driven Dermatologic And Gastrointestinal Diseases, Subject To Additional Funding

Article summary

Related companies

Comments —